Trial reportMolecular medicine (Cambridge, Mass.)2012
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Trial report in Molecular medicine (Cambridge, Mass.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Systematic Review of Erythropoietin (EPO) for Neuroprotection in Human Studies.Neurochemical research · 2021Pooled it
- The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Quality of Life in Painful Peripheral Neuropathies: A Systematic Review.Pain research & management · 2019Pooled it
- Managing fatigue in sarcoidosis - A systematic review of the evidence.Chronic respiratory disease · 2017Pooled it
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015Trial
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.Molecular medicine (Cambridge, Mass.) · 2013Trial
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.Current pain and headache reports · 2026Review
- Use of fatigue assessment scale and small fiber neuropathy screening list in Japanese patients with sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Mechanisms of ARA290 in counteracting cadmium-triggered neurotoxicity in PC12 cells.Toxicology research · 2025Article
- Editorial: Cardiovascular inflammaging: basic and translational aspects.Frontiers in cardiovascular medicine · 2024Article
- A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.Pulmonary therapy · 2021Review
- Prevalence and characteristics of self-reported hypothyroidism and its association with nonorgan-specific manifestations in US sarcoidosis patients: a nationwide registry study.ERJ open research · 2021Article
- Erythropoietin and its derivatives: from tissue protection to immune regulation.Cell death & disease · 2020Review
- Management of neurosarcoidosis: a clinical challenge.Current opinion in neurology · 2019Review
- Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus.Journal of cellular and molecular medicine · 2018Article
- Role of the β Common (βc) Family of Cytokines in Health and Disease.Cold Spring Harbor perspectives in biology · 2018Review
- Mirogabalin and emerging therapies for diabetic neuropathy.Journal of pain research · 2018Review
- Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the Small Fiber Neuropathy Screening List (SFNSL) in sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.Scientific reports · 2017Article
- Patient reported outcome measures (PROMs) in sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing) reduces allodynia in preclinical neuropathy models. We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in patients with sarcoidosis. A total of 22 patients diagnosed with sarcoidosis and symptoms of SFN were enrolled in a double-blind, placebo-controlled exploratory trial consisting of three times weekly intravenous dosing of ARA 290 (2 mg; n = 12) or placebo (n = 10) for 4 wks. Inclusion criteria were a diagnosis of neuropathy and a spontaneous pain score of ≥5 (Brief Pain Inventory [BPI]). Endpoints assessed were changes in pain intensity and the small fiber neuropathy screening list (SFNSL) score, quality of life (SF-36), depressive symptoms (Inventory of Depressive Symptomatology [IDS]) and fatigue (Fatigue Assessment Scale [FAS]). No safety concerns were raised by clinical or laboratory assessments. The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo (Δ -11.5 ± 3.04 versus Δ -2.9 ± 3.34 [standard error of the mean]). Additionally, the ARA 290 group showed a significant change from baseline in the pain and physical functioning dimensions of the SF-36 (Δ -23.4 ± 5.5 and Δ -14.6 ± 3.9, respectively). The mean BPI and FAS scores improved significantly but equivalently in both patient groups. No change was observed in the IDS. ARA 290 appears to be safe in patients with sarcoidosis and can reduce neuropathic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.